Glucose Monitoring App Snapshot draft MEDICAL DEVICE OEM C O N T I N U O U S G L U C O S E M O N I T O R I N G S Y S T E M • Adapt to strict processing requirements of a secondary operation put in place to manufacture a new device model • Meet material size and thickness requirements while achieving desired color target • Overcome material unpredictability and sensitivity to heat, light and moisture • Minimize impact of supply chain instability and changes • Offered support for processing under low pressure conditions and at every stage of manufacturing • Performed extensive R&D work to consistently deliver the customer’s color target of a hard-to-achieve light gray • Effectively addressed all material challenges and sensitivities • Provided regular ‘summaries of understanding’ to keep up with changing forecasts and ordering patterns Mevopur™ Pre-color Formulation KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/polymer-colorants/solid-color-masterbatches/mevopur-custom-colors-and-formulations

 Strong past performance demonstrates that our strategy and execution are working  Megatrends and emerging opportunities align with our strengths  Innovation and services provide differentiation, incremental pricing power, and competitive advantage  Strong and proven management team driving growth and performance  Addressable market exceeds $40 billion Schedule I Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Below is a reconciliation of non-GAAP financial measures to the most directly comparable measures calculated and presented in accordance with U.S. ��PolyOne Investor Presentation�Goldman Sachs 2014 US Emerging / SMID Cap Growth Conference�New York, NY�November 20, 2014�� Forward-Looking Statements Use of Non-GAAP Measures PolyOne Commodity to Specialty Transformation PolyOne�At A Glance Mix Shift Highlights Specialty Transformation Confirmation of Our Strategy Strategy and Execution Drive Results Proof of Performance & 2015 Goals 32% Adjusted EPS CAGR from 2011 Innovation Drives Earnings Growth A Rich Pipeline of Opportunity Megatrends Aligned with Key End Markets Debt Maturities & Pension Funding – 9/30/14 Free Cash Flow and Strong Balance Sheet �Fund Investment / Shareholder Return PolyOne Core Values Why Invest In PolyOne? Non GAAP Rec - 11 5 14.pdf Sidoti & Company non-GAAP Rec

These devices need to be durable, lightweight, and biocompatible to ensure users’ safety and comfort. Mevopur™ Healthcare Functional Additives Mevopur™ Healthcare Colorants and Formulations

Mevopur™ Healthcare Functional Additives MEVOPUR™ Needle Hub Learn more about how Avient's medical-grade polymers, colorants and additives can enhance effectiveness and safety.

Users shall store any personal files, notes, pictures, and emails in a separate and clearly identifiable folder labelled “PERSONAL EMAIL” or “PERSONAL FILES” such that Personal Data is always separate and readily distinguishable within Information Systems from Avient Data or otherwise Confidential Data. http://polynet/ethics/Portals/23/documents/Cyber%20and%20Data%20Incident%20Response%20Policy/Cyber_Incident_Response_Policy-September%202018_EN%20-%20v1.pdf http://polynet/ethics/Portals/23/documents/Cyber%20and%20Data%20Incident%20Response%20Policy/Cyber_Incident_Response_Policy-September%202018_EN%20-%20v1.pdf Confidential 6 Avient IT Department Information Systems Use Policy September 1, 2021 APPENDIX A: DEFINITIONS In addition to those terms defined within the body of this Policy, the following definitions are used: “Avient Data” – includes (a) all data and information generated, stored, collected, or processed by Avient through Information Systems; (b) all information under the control of Avient and originating from, belonging to, or received from customers, suppliers, or third parties; (c) all data and information regarding intellectual property of Avient; and (d) purely intra-Avient information connected to individual employees, such as Information System usernames, passwords, and company ID. Confidential Data” – all confidential or proprietary information, including any Avient Data, Personal Data, and third party data accessible or stored on Information Systems.

Technical Data Sheets Safety Data Sheets Safety Data Sheets

Technical Data Sheets Safety Data Sheets Safety Data Sheets

Technical Data Sheets Safety Data Sheets Safety Data Sheets

Avient to highlight its range of colorants and additives for medical applications at Pharmapack 2025, including its ever-expanding Mevopur™ Healthcare Colorants and Formulations, to help accelerate the development of healthcare products and mitigate the risk of non-compliance Avient’s Mevopur™ Healthcare Colorants and Formulations, along with Mevopur™ Healthcare Functional Additives, were introduced to the market 15 years ago. Our Mevopur portfolio is constantly growing and adapting, but what remains unchanged is our commitment to helping our customers make high-quality healthcare products,” said Volker Dickfeld, Sr.

GUIDANCE 8 15.4% 15.9% Adjusted EBITDA Margin % Better-than-expected margins driven by: • Favorable mix - strong demand for composite applications • Raw material deflation Q2 EBITDA BRIDGE 9 ($ millions) CAI: Price / Mix 7) Deflation 11) SEM: Price / Mix 2) Deflation 6) Net Price Benefit 26) Wage and Energy Inflation (10) Cost Reductions 13) FX (2) Q2 2023 Actual $131) Adjusted EBITDA Q2 2022 Pro Forma $ 172) Demand (68) • Demand conditions vs. expectations: LATAM • Net price benefit remains greater than wage and energy inflation • Clariant synergies and reduced administrative costs Q2 2023 SEQUENTIAL SALES BY REGION Q 2 2 0 2 3 v s . Global Compact • Highlights ESG Performance, including ratings, awards, and certifications • Features increased carbon emissions disclosures, including Climate Change Scenario Analysis and Scope 3 emissions data • Outlines Sustainable Supplier Program, designed to enable supplier evaluation & collaboration • Reflects Great Place To Work® culture focused on safety, employee engagement and advancing diversity, equity and inclusion 2022 SUSTAINABILITY REPORT 15 Avient Confidential 16 • Virtual presentation to be held September 20, 2023 • Leadership will be conducting an investor-focused presentation around our sustainable solutions portfolio • Deep dive into how we enable customers to achieve their sustainability goals SUSTAINABILITY DAY 16 …are Growing at Twice the Rate as Conventional Products Sustainably-Branded Products… STAKEHOLDER INFLUENCE DRIVES DEMAND Consumers Are demanding recyclability and eco- conscious products Governments Are mandating changes through legislation, taxes, and regional accords Brand Owners Have committed to ambitious goals to achieve sustainability metrics 17 AP P EN D IX 20 Performance Additives 16% Pigments 12% TiO2 Dyestuffs 2% Polyethylene Nylon Polypropylene Styrenic Block Copolymer Other Raw Materials 33% ~40% hydrocarbon based (Grey shaded materials are hydrocarbon based, includes portion of “Other Raw Materials”) Non-hydrocarbon based materials 2022 pro forma results for the acquisition of Avient Protective Materials RAW MATERIAL BASKET PEER COMPARISONS AVIENT IS ASSET LIGHT Capex / Revenue 2023E (%) Avient Specialty Other Specialty / Note: Avient reflects 2023 estimated revenue of $3,280 and estimated run-rate CAPEX of $110M. 22 3 2 3 3 4 4 3 3 4 5 5 7 8 8 FREE CASH FLOW CONVERSION Note: Free cash flow conversion calculated as (Adjusted EBITDA – Capex) / Adjusted EBITDA. Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years. 24 EV / 2023E EBITDA Historic Multiple 6.5 8.3 10.3 14.4 13.6 13.6 12.4 9.0 20.2 18.2 11.5 10.6 9.7 9.6 8.7 8.3 01 1) 01 8) 02 3) Avient Specialty Other Specialty / SEGMENT DATA U.S. & Canada 40% 37% 18% 2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS 20% 24% Building and END MARKET REVENUE $2,355M $402M $1,300M $272M Sales EBITDA Specialty Engineered Materials Color Additives and Inks $592M$3,653M (1) 9% 26 (1) Total company sales and adjusted EBITDA of $3,653M and $592M, respectively, include intercompany sales eliminations and corporate costs 2022 REVENUE | $2 .4 B ILL ION 34% 38% 20% END MARKET REGION 27 34% 21% Building & 1% Energy 2% COLOR, ADDITIVES & INKS 2022 PRO FORMA REVENUE | $1 .3 B ILL ION 52% 35% 28 19% 8%Industrial 16% 9% Defense Building & END MARKET REGION SPECIALTY ENGINEERED MATERIALS 32% 27% 14% Building & 3% 1% Defense 1% (18% of sales) 9% 2022 PROFORMA AVIENT REGIONAL SALES 27% 14% 17% Building & (37% of sales)Transportation 24% 12% Building & US & Canada (40% of sales) 7% 56% 23% 7% Building & 1% LATAM (5% of sales) 3% 29 BY END MARKET Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.